Status:
COMPLETED
Safety and Efficacy of an Investigational Drug in Human Immunodeficiency Virus (HIV)-Infected Patients Failing Current Antiretroviral Therapies (0518-005)(COMPLETED)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
HIV Infections
Acquired Immunodeficiency Syndrome
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study will investigate the safety and efficacy of different doses of an investigational drug (MK0518) as a therapy for HIV-infected patients failing current antiretroviral therapies.
Eligibility Criteria
Inclusion
- Patient must be HIV positive with Human Immunodeficiency Virus (HIV) Ribonucleic Acid (RNA) values that are within ranges required by the study
- Patient must be currently on antiretroviral therapy (ART)
Exclusion
- Patient less than 18 years of age
- Additional exclusion criteria will be discussed and identified by the study doctor
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2009
Estimated Enrollment :
179 Patients enrolled
Trial Details
Trial ID
NCT00105157
Start Date
March 1 2005
End Date
July 1 2009
Last Update
December 4 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.